Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amphivena Therapeutics Inc.

Division of Affimed NV
www.affimed.com

Latest From Bayer AG

More Than CAR-T: Hematologic Oncology Pipeline Offers Rich Menu Of Possible Approvals

Sponsors of established products like Amgen's Kyprolis and Blincyto and Bristol's Sprycel work to bulk up labeling with new indications while FDA reviews at least six novel agents for blood cancers.

Approvals Cancer

Pipeline Watch: Phase III Starts With Fitusiran In Hemophilia, Zoliflodacin In Gonorrhea, Opdivo Combo In RCC

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Provenge To Drive Sanpower Growth And Wider China Cell Therapy Market?

China will provide a rising market potential for Sanpower’s newly acquired Dendreon and its Provenge product for prostate cancer, as part of the Chinese firm’s broader strategy, and the deal could also have an impact on the regulatory climate for cellular immunotherapies in China.

China Commercial

Antibiotic Pipeline Profile: Targeting Delivery To Infection Site

Among the antibiotics that have garnered a qualified infectious disease product designation, a collection of late-stage products are targeted at local delivery, especially inhaled and vaginal formulations.

Infectious Diseases Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Affimed NV
  • Senior Management
  • Contact Info
  • Amphivena Therapeutics Inc.
    Phone: 6221-65307
    Technologiepark
    Im Neuenheimer
    Heidelberg, 69120
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register